Real-Time Bidirectional Pyrophosphorolysis-Activated Polymerization for Quantitative Detection of Somatic Mutations

Najie Song, Xueting Zhong, Qingge Li*

Engineering Research Centre of Molecular Diagnostics, Ministry of Education, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, Fujian, China

Abstract

Detection of somatic mutations for targeted therapy is increasingly used in clinical settings. However, due to the difficulties of detecting rare mutations in excess of wild-type DNA, current methods often lack high sensitivity, require multiple procedural steps, or fail to be quantitative. We developed real-time bidirectional pyrophosphorylisis-activated polymerization (real-time Bi-PAP) that allows quantitative detection of somatic mutations. We applied the method to quantify seven mutations at codons 12 and 13 in KRAS, and 2 mutations (L858R, and T790M) in EGFR in clinical samples. The real-time Bi-PAP could detect 0.01% mutation in the presence of 100 ng template DNA. Of the 34 samples from the colon cancer patients, real-time Bi-PAP detected 14 KRAS mutant samples whereas the traditional real-time allele-specific PCR missed two samples with mutation abundance <1% and DNA sequencing missed nine samples with mutation abundance <10%. The detection results of the two EGFR mutations in 45 non-small cell lung cancer samples further supported the applicability of the real-time Bi-PAP. The real-time Bi-PAP also proved to be more efficient than the real-time allele-specific PCR in the detection of templates prepared from formalin-fixed paraffin-embedded samples. Thus, real-time Bi-PAP can be used for rapid and accurate quantification of somatic mutations. This flexible approach could be widely used for somatic mutation detection in clinical settings.

Introduction

Somatic mutations in most cancers represent molecular signatures that are valuable for prognosis prediction and treatment management. For example, the KRAS mutations in codons 12 and 13 are predictive markers of nonresponse to anti-epidermal growth factor receptor (anti-EGFR) antibodies like cetuximab [1] and panitumumab [2]. Mutations in EGFR can confer sensitivity or resistance to EGFR tyrosine kinase inhibitors such as gefitinib [3] and erlotinib [4] in patients with advanced non-small-cell lung cancer (NSCLC). However, detection of somatic mutations poses a technical challenge owing to the presence of large excess of wild-type DNA in tumor samples. This difficulty has been addressed by a wide range of molecular techniques for mutation detections. Methods commonly used include restriction enzyme digestion of wild-type DNA [5,6,7], peptide nucleic acids (PNA) suppression of wild-type elongation [8,9,10,11], allele-specific amplification [12,13,14], sequence-specific ligation [16], and COLD-PCR [17]. More recently, digital PCR based on the compartmentalization and amplification of single DNA molecules [18,19,20] and deep sequencing based on next generation sequencing technology [21] are also proposed for increased sensitivity or multiplexity. However, most of these methods are inconvenient for use in clinical laboratories due to the insufficient selectivity, high costs, long turnaround time or complex manipulations.

In addition, with the advent of personalized medicine, there is a compelling need for quantitative measurement of somatic mutation level that may uncover critical pathological information in cancer studies. For example, a portion of patients characterized as being wild-type for KRAS fail to respond to anti-EGFR antibody therapy. One potential explanation is that some patients classified as wild-type for KRAS may have low, but clinically significant, levels of KRAS mutations. Currently, there is no evidence that small KRAS mutant subpopulations are affecting clinical outcomes with respect to EGFR-directed therapies. However, it will be necessary to quantitatively measure the levels of KRAS mutation to determine what level of KRAS mutation does predict failure to respond to therapies directed against the EGFR [22,23]. In another example, circulating tumor DNA in plasma or serum could serve as a ‘liquid biopsy’ for numerous diagnostic applications and would avoid the need for tumor tissue biopsies [24]. One distinct feature of liquid biopsy is that it enables quantification of the mutant DNA levels. By taking repeated blood samples, the mutant level in circulating DNA can be traced during the natural course of the disease or during cancer treatment, allowing a precise monitoring of the disease status. Unfortu-
nately, the difficulties in the detection of somatic mutations render the quantification an even more challenging task.

In clinical settings, samples of tumor tissue gathered during biopsy or resection are usually in the form of formalin-fixed paraffin-embedded (FFPE) diagnostic blocks, however, DNA templates prepared from FFPE tissues are of inferior quality as compared to their frozen counterparts owing to degradation of DNA caused by formalin fixation [25,26]. Similar DNA fragmentation was also found in the circulating tumor DNA [27]. DNA fragmentation further narrows the range of choice for the detection methods to those only work on short DNA templates.

Pyrophosphorolysis-activated polymerization (PAP) is a method for highly specific nucleic acid amplification [28,29], where pyrophosphorylation and polymerization are serially coupled by DNA polymerase using PAP primers, which are blocked at their 3’ termini with dideoxynucleotides. By using bidirectional PAP (Bi-PAP), which is performed with a pair of opposing PAP primers that overlap by one nucleotide at their 3’ termini, great improvement in specificity could be achieved [30,31]. So far, PAP or Bi-PAP works mainly in a polyacrylamide gel electrophoresis mode, which is time-consuming, non-quantitative, and amenable to carry-over contamination. On the other hand, real-time PCR detection is a well-established approach, which features selectivity. The Bi-PAP reaction was performed in a total volume of 25 µl including 5 µl of DNA template, 50 mM Tris-HCl (pH 7.8), 16 mM (NH₄)₂SO₄, 5.5 mM MgCl₂, 25 mM each of dNTP, 90 µM Na₂P₂O₇, 2% dimethylsulfoxide (DMSO), 5 U of KlenTaq-S (Sciencetech Corp, St. Louis, MO), and optimized concentrations of primers as follows: 0.2 µM forward primer, 0.04 µM (G12V, G12S, G12R, G12D) or 0.08 µM (G12C, G12A, G13D) reverse primer, and 0.2 µM probe 1 for each mutation. The cycling conditions consisted of an initial denaturation step at 96°C for 3 minutes followed by 60 cycles of 95°C for 20 s, 60°C for 30 s, 72°C for 30 s. Fluorescence was monitored at 60°C in each cycle.

Serial dilutions of plasmid DNA of mutants containing 5, 50, 500, and 5000 copies per reaction, respectively, were used to determine the specificity of the reaction. Serial dilutions of wild-type human genomic DNA containing 1, 10, 100, and 500 ng per reaction, respectively, were used to assess the specificity of the reaction. Real-time Bi-PAP assays were carried out in Stratagene MX3005p (Agilent technologies, Santa Clara, CA). The baseline and the quantification cycle (Cq) were set using the machine software version 4.10.

Duplex Two-color Real-Time Bi-PAP Assay for KRAS Mutations

The reaction mixture consisted of 0.2 µM mutation specific forward primer, 0.04 µM (G12V, G12S, G12R, G12D) or 0.08 µM (G12C, G12A, G13D) reverse primer, 0.2 µM probe 1, 0.008 µM exon-4F, 0.04 µM exon-4R, 0.04 µM probe 3, and 5 µl of template containing certain percentage of mutation in the presence of 100 ng wild-type genomic DNA. All other components in the mixture as well as the cycling conditions were identical with the singleplex assay. In this reaction, primer exon-4F and exon-4R were used to amplify a region of exon 4 of KRAS, which was conservative and used as an internal

PAP Primers

PAP primers were designed using Primer premier 5.0 (PREMIER Biosoft International, Palo Alto, CA). Bi-PAP primers for seven KRAS mutations, two EGFR mutations, and the corresponding primers for internal controls were designed (Table S1). Three tags attached to the PAP primers were artificially generated and confirmed to have no significant similarity with any known human genomic sequences in NCBI through BLAST analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Three molecular beacons were designed according to the guidelines (www.molecular-beacons.com) to hybridize with the reverse complement of the tags. All the PAP primer precursors (without 3’-terminal dideoxynucleotide) and probes were synthetized by Sangon (Shanghai, China).

PAP primers were prepared from their precursors by adding 3’-terminal dideoxyribonucleotides through terminal deoxynucleotidyl transferase (TaKaRa Inc., Dalian, China) and purified by polyacrylamide gel electrophoresis. The quality of PAP primers was checked by determining the molecular weight of the oligonucleotides using Relex III MALDI-TOF MS (Barker Daltonik, Bremen, Germany) followed by regular PCR at pH 0.3, where pyrophosphorylation was inhibited. The PCR products should be negative with the PAP primers but positive with the PAP primer precursors [28,29].

Singleplex Real-Time Bi-PAP Assay

Singleplex real-time Bi-PAP assay was used to optimize the reaction conditions and to assess the sensitivity, specificity, and selectivity. The Bi-PAP reaction was performed in a total volume of 25 µl including 5 µl of DNA template, 50 mM Tris-HCl (pH 7.8), 16 mM (NH₄)₂SO₄, 5.5 mM MgCl₂, 25 µM each of dNTP, 90 µM Na₂P₂O₇, 2% dimethylsulfoxide (DMSO), 5 U of KlenTaq-S (Sciencetech Corp, St. Louis, MO), and optimized concentrations of primers as follows: 0.2 µM forward primer, 0.04 µM (G12V, G12S, G12R, G12D) or 0.08 µM (G12C, G12A, G13D) reverse primer, and 0.2 µM probe 1 for each mutation.
To differentiate the target and internal control, probe 1 for mutation detection was labeled with FAM and the probe 3 for internal control detection was labeled with ROX. Quantification of mutant percentage was achieved through a calibration curve obtained by plotting the Cq difference between the mutation and the internal control (\(\Delta\text{Cq} = \text{Cq} - \text{CqIC}\)) with respect to the logarithmic mutant percentage.

Frozen tissue samples stored at \(-80\) °C were collected from 34 colorectal cancer patients in Zhongshan Hospital of Xiamen (Xiamen, Fujian, China). DNA was extracted from frozen tissues using QIAamp DNA Mini kit (Qiagen). For comparison, these samples were also detected by a commercial diagnostic kit AmoyDx KRAS (Amoy Diagnostics Inc., Xiamen, China), which is a real-time ARMS PCR assay. For confirmation, these samples were further analyzed by DNA sequencing using a pair of primers encompassing codons 12 and 13 of KRAS: 5'-AGGTACTGGTGGAGTATTTGATA-3' (forward) and 5'-TTTATCTGTATCAAAGAATGGTCCT-3' (reverse).

**Triplex Three-color Real-time Bi-PAP Assay for EGFR Mutations**

The reaction mixture consisted of 0.2 \(\mu\)M L858R-F, 0.08 \(\mu\)M L858R-R, 0.2 \(\mu\)M T790M-F, 0.08 \(\mu\)M T790M-R, 0.12 \(\mu\)M Exon2-F, 0.024 \(\mu\)M Exon2-R, 0.2 \(\mu\)M probe 1, 0.2 \(\mu\)M probe 2, and 0.12 \(\mu\)M probe 3. All other components in the mixture as well as the cycling conditions were identical with the singleplex assay.

Frozen tissue samples stored at \(-80\) °C were collected from 20 NSCLC patients in Fujian Provincial Cancer Hospital (Fuzhou, Fujian, China). FFPE tissue samples were collected from 25 NSCLC patients in Zhongshan Hospital of Xiamen. DNA from frozen tissues was extracted as described above. DNA from FFPE tissues was extracted using QIAamp DNA FFPE Tissue kit (Qiagen). For comparison, these samples were detected by two commercial diagnostic kits AmoyDx EGFR (Amoy Diagnostics Inc) and TheraScreen EGFR RGQ PCR (Qiagen), both of which are real-time ARMS PCR assays. For confirmation, all these samples were analyzed by DNA sequencing using the following primers: 5'-CTTCTTCCCATGATGATCTGTC-3' (forward) and 5'-AACATACAGC-GATGGAAGG-3' (reverse) for L858R; 5'-CGTAAACGTCCCTGTGCTA-3' (forward) and 5'-GACCGCATGTGAGGAT-3' (reverse).

**Ethics Statement**

The study protocol for sample collection was approved by Research Ethics Committee of Xiamen University and an informed consent was signed for each patient.

**Results**

**Working Principle of Real-Time Bi-PAP**

Real-time Bi-PAP was designed by introducing a tag sequence to one of the Bi-PAP primers and a fluorogenic probe in the reaction can hybridize with the reversely complementary sequence of the tag (Figure 1). The working principle can be described as follows: 1) Annealing: Forward and reverse primers hybridize with the target DNA, resulting a fully matched hybridization for the mutant template and a 3'-terminal mismatch for the wild-type template. 2) Pyrophosphorylation: The matched primers lose their 3' terminal deoxyribonucleotides catalyzed by the pyrophosphorylase activity of KlenTaq-S and become unblocked whereas the 3'-termini mismatched primers stay blocked. 3) Primer extension and probe hybridization: The unblocked primers are elongated by the polymerase activity. After the extension is complete, the probe hybridizes with the reverse complement of the tag and becomes fluorescent. 4) Detection: Fluorescence is detected in each cycle and an amplification curve is generated. The wild-type template cannot be amplified because the two Bi-PAP primers remained blocked owing to 3'-terminal mismatch, leading to no extension for probe hybridization and thus no fluorescence signal.

**Working Conditions of Real-Time Bi-PAP**

We first studied the working conditions of real-time Bi-PAP using KRAS G12R mutation as a model analyte. We followed the regular PAP working conditions but with different molar ratios of the tagged primer to the untagged primer (0.5:5, 1:5, 2:5, 3:5, 4:5 and 5:5). We observed that no amplification signals occurred when the amount of the two primers were equal. As the concentration of the tagged primer decreased, amplification signal became stronger. The strongest signal was obtained when the ratio was 1:5. Similar results were found in the detection of other mutations of KRAS. We therefore concluded that an asymmetric amplification with excess tagged primers is required for real-time Bi-PAP.

**Analytical Performance of Singleplex Real-Time Bi-PAP**

We evaluated the sensitivity, specificity, and selectivity of real-time Bi-PAP as defined for PAP [29]. Using KRAS G12R mutation as an example, we first determined the sensitivity with serial 10-fold dilutions of plasmid DNA in 10 replicates. The results showed that all dilutions could be detected repeatedly and the sensitivity was determined to be 5 copies per reaction (Figure 2). The specificity was tested with serial 10-fold dilutions of wild-type genomic DNA extracted from 293T cells in 10 replicates. The results showed that only 500 ng per reaction occasionally gave weak signals in the late cycles while all other dilutions consistently gave no signals. The specificity was thus determined to be 100 ng per reaction (\(\sim 30,000\) copies per reaction). The selectivity was calculated by the ratio of sensitivity to specificity as 1.67 \(\times\) 10\(^{-4}\). Similar results were obtained from other six KRAS mutations except for G12C, which had a specificity of 500 ng and selectivity of 3.3 \(\times\) 10\(^{-3}\). The analytical performance of real-time Bi-PAP was comparable with a regular Bi-PAP [30].

**Two-color, Duplex Real-Time Bi-PAP Assay for KRAS Mutations**

A two-color, duplex real-time Bi-PAP for KRAS mutations and an internal control was constructed for mutation quantification. We first studied the quantification range of this duplex Bi-PAP by serial 10-fold dilutions of mutant plasmids in the presence of 100 ng wild-type genomic DNA. By plotting the Cq difference between the mutation and the internal control (\(\Delta\text{Cq} = \text{Cq} - \text{CqIC}\)) with respect to the logarithmic mutation percentage from 100\% to 0.01\%, a linear relationship was achieved (Figure 3). Of note, the Cq \(\text{L858R}\) kept nearly constant regardless of the mutation percentages, demonstrating the negligible influence from the mutation target on the amplification of internal control, therefore ensuring the accuracy for mutation quantification.

Occasionally, we observed some non-specific, though weak, amplification signal from 100 ng wild-type DNA in the late cycles. During the experiments, we actually sequenced part of these false amplification products, and all of them had the sequence concordant with the PAP primers. These false results could exert influence on the limit of detection. To clarify their
origin, we performed real-time Bi-PAP with both 100 ng wild-type genomic DNA and no-template control (NTC) in 10 replicates. The results showed that non-specific amplification signal only came from the wild-type genomic DNA samples but never from NTC. We thus concluded that the non-specific amplification was caused by “mis-priming” rather than primer dimer, which were not formed in real-time Bi-PAP. Similar results were observed from G12D, G12A, G12V, G12S, and

Figure 1. Working principle of real-time Bi-PAP. The working principle is schematically illustrated for the detection of a mutant template (shown as GC-containing, left panel) using a pair of Bi-PAP primers and a molecular beacon. The four steps: primer annealing, pyrophosphorolysis, primer extension/probe hybridization, and fluorescence detection, are shown from the top to bottom. As a result, fluorescence generated from the probe hybridization is detected in the form of amplification profile. In case of a wild-type template (shown as TA-containing, right panel), two Bi-PAP primers cannot be activated and extended owing to 3'-terminal mismatch, leading to no probe hybridization and thus no fluorescence signal. doi:10.1371/journal.pone.0096420.g001

Figure 2. Study on the sensitivity and specificity of the singleplex real-time Bi-PAP. (A) Amplification curves of 5000, 500, 50, 5 copies per reaction (from the left to right) of G12R mutant plasmids. (B) Amplification curves of 500, 100, 10, 1 ng wild-type genomic DNA per reaction. Water was used as non-template control (NTC). doi:10.1371/journal.pone.0096420.g002
G12R except from G12C and G13D where no false positive signals were detected.

To determine the limit of detection, we analyzed two mixtures containing 0.01% and 0.1% mutant for each mutation type of KRAS in 10 replicate and calculated $D_{Cq}$. The limit of detection should have a $D_{Cq}$ value not overlapped with 100 ng wild-type DNA by means of either “mean ± SD” or “minimum to maximum”. According to this prerequisite, the limit of detection was 0.1% for G12A, G12S, and G13D; 0.01% for G12D, G12V, G12R, and G12C, respectively (Figure 4).

We analyzed 34 frozen tissue samples collected from colorectal cancer patients. For comparison, these samples were also analyzed in parallel by DNA sequencing and the commercial kit. Of the 34 samples, 14 samples were mutant by real-time Bi-PAP. Of these 14 mutant samples 12 were concordantly identified by the real-time ARMS PCR kit. The two missed mutant samples had the mutant percentage (0.07% and 0.26%) lower than the limit of detection of the real-time ARMS PCR kit (1%). DNA sequencing only identified five samples with mutant percentage higher than 10%, while the other nine mutant samples (mutant percentage <10%) were all undetected (Table S2). The above results suggested that real-time Bi-PAP is the most sensitive method for KRAS mutation detection, followed sequentially by the real-time ARMS PCR kit and the DNA sequencing analysis.
Three-color, Triplex Real-Time Bi-PAP Assay for EGFR Mutations

A three-color, triplex real-time Bi-PAP assay was established for simultaneous detection of L858R, T790M, and an internal control. We first studied the quantification range of this triplex Bi-PAP by serial dilutions of mutant genomic DNA (from H1975 cell line) in the presence of wild-type genomic DNA (from 293T cell line) with the total amount of the template DNA kept at 100 ng. By plotting the Cq difference between the mutation and the internal control with respect to the logarithmic mutation percentage from 50% to 0.01%, a linear relationship was obtained (Figure 5). The limit of detection was determined using mixtures containing 0.1%, 0.01%, and 0% mutant genomic DNA with the overall template DNA kept at 100 ng. From 10 replicate detection results, the limit of detection was determined to be 0.01% for L858R and T790M.

Using the triplex three-color real-time Bi-PAP, we analyzed 20 frozen tissue samples and 25 FFPE tissue samples collected from NSCLC patients. For comparison, these samples were also analyzed in parallel by the two commercial diagnostic kits and DNA sequencing. Of the 45 samples, 10 samples were mutant by real-time Bi-PAP. These 10 mutant samples were also concordantly identified by the two real-time ARMS PCR kits. Among the 10 samples, DNA sequencing identified five samples that had relatively high mutant percentages (Table S3).

Performance of Real-Time Bi-PAP in Analyzing FFPE-derived DNA

The template length of real-time Bi-PAP is one base shorter of the combined lengths of the two primers. Such a short template should render Bi-PAP more suitable for the fragmented DNA derived from FFPE tissue samples than those real-time ARMS PCR assays, which require much longer templates that need to encompass the binding regions for two primers and one probe. To test this assumption, we analyzed 25 FFPE samples and 20 frozen tissue samples using real-time Bi-PAP and the two real-time ARMS PCR kits, respectively. The amplification results from the internal control of each assay allowed a direct comparison between their performances. As shown in Figure 6, the frozen tissue-derived DNA template had earlier amplification signals than its counterpart FFPE tissue-derived DNA template in all cases. However, amplification cycles between the two sample types were very close with each other in real-time Bi-PAP whereas FFPE samples significantly lagged behind those from frozen tissue samples in the two real-time ARMS PCR kits. Calculation of the average Cq values from the two template types resulted in the smallest difference in real-time Bi-PAP. We therefore concluded that real-time Bi-PAP is more efficient than real-time ARMS PCR in the analysis of FFPE-derived DNA.

Discussion

We developed the real-time Bi-PAP for quantification of somatic mutations. The uniqueness of this method is that pyrophosphorolysis, polymerization, probe hybridization, and fluorescence detection is accomplished in a closed tube and the

Figure 5. Quantitative performance of the three-color triplex real-time Bi-PAP. Amplification curves of 50%, 10%, 1%, 0.1%, 0.01%, and 0% mutant (from left to right) are shown for L858R (A) and T790M (B) in the upper panel. The linear relationship of the Cq difference between the mutation and the internal control (∆Cq = Cq – CqIC) with respect to the logarithmic mutation percentages are shown in the lower panel. Amplification curves of the internal control (C) with different mutant percentages are shown in the upper panel. The linear relationship between the Cq values of the internal control and the logarithmic mutant percentages is given in the lower panel.

doi:10.1371/journal.pone.0096420.g005
The high specificity of real-time Bi-PAP was demonstrated in the two examples of this study. In the detection of seven \( KRAS \) mutations, four mutations (G12D, G12V, G12R, and G12C) had a limit of detection of 0.01% and three other mutations (G12A, G12S, and G13D) had 0.1% in the presence of 100 ng wild-type template. For the two \( EGFR \) mutations (L858R and T790M), the limit of detection was 0.01% with both mutant types. This specificity level was close to the digital methods such as BEAMing [33] and digital PCR [20], and was at least 10-folds higher than the ARMS method. As demonstrated in the clinical studies, real-time Bi-PAP not only identified all those mutation-containing samples detected by the real-time ARMS kit and DNA sequencing, it also could identify those <1% mutant samples missed by the ARMS kit and DNA sequencing.

The quantification accuracy of real time Bi-PAP was ensured by the inclusion of an internal control in the reaction. The use of internal control for accurate gene quantification is well-established in real-time PCR [34]. In real-time Bi-PAP, the internal control represented the sum of wild-type and the mutant. The \( C_{q} \text{IC} \) values could be used to indicate the reproducibility of the detection once the input template was constant. As shown in the \( KRAS \) and \( EGFR \) mutation detection, when the overall template DNA was 100 ng, the \( C_{q} \) values of the internal controls kept nearly constant regardless of the mutant percentages. This result suggested that the internal positive control could be independently amplified to embody the amount of the overall template. In this study, we kept the input template at 100 ng and used \( C_{q} = C_{q} - C_{q} \text{IC} \) as a measure to eliminate the well-to-well and sample-to-sample variations that may exist in quantification of different samples. These measures ensured the accuracy of the quantification.

Real-time Bi-PAP involved a single-step manipulation, and the entire procedure can be finished within 3 h. It is also cost effective when considering real-time PCR machine is now commonly used in most clinical molecular pathology laboratories. Finally, the results from the comparison study using frozen and FFPE samples showed that real-time Bi-PAP, which requires template no longer than the overall length of the two primers, was indeed more tolerable to potential fragmentation from FFPE-derived DNA than the real-time ARMS methods that rely on more intact template.

The above advantages of real-time Bi-PAP were also recognized in a recent study, where a dye-based real-time Bi-PAP assay was developed and validated for the detection of three tumor-specific mutations in circulating cell-free DNA of patients with uveal melanoma [35]. This assay allowed a quantitative detection of circulating tumor DNA in plasma from patients with metastatic uveal melanoma. The sensitivity and specificity in the detection of the three mutations obtained in this study were similar to those achieved in the present study. However, this dye-based real-time approach excluded the use of multiplex approach and therefore an internal control cannot be used for more precise quantification. In addition, the multiplexing detection cannot be further explored with this method.

The multiplexing ability of our approach may find flexible applications in clinical settings. Current real-time ARMS PCR often have more than 10 primers mixed together in a single reaction, enabling simultaneous detection of multiple mutations but at the cost of specificity restricted to 1–5% [36,37]. According to ARMS, an error in primer recruitment would generate a template of the opposite allele, leading to exponential amplification of the error-containing template. In contrast, the specificity of real-time PAP is within 0.1–0.01%, which is at least 10-fold higher than the ARMS. This is because an error in PAP primer

![Figure 6. Performance comparison of real-time Bi-PAP and real-time ARMS PCR in the detection of template DNA derived from frozen tissue and FFPE tissue samples. (A) Real-time Bi-PAP. (B) TheraScreen \( EGFR \) RGQ PCR. (C) AmoyDx ARMS \( EGFR \). Amplification curves shown are from 20 frozen tissue samples (black lines) and 25 FFPE tissue samples (red lines), respectively. The difference between the average amplification \( C_{q} \) values (indicated with a double-headed arrow) from the two types of samples are given for each assay in the detection of the internal control. doi:10.1371/journal.pone.0096420.g006](#)
In conclusion, we have demonstrated that real-time Bi-PAP can be used for the rapid and accurate quantification of somatic mutations. This flexible approach could be widely used for somatic mutations in clinical settings before digital PCR becomes commonly accessible and economically affordable.

Supporting Information

Table S1  Primers and probes used in real-time Bi-PAP. (DOCX)

Table S2  Summary of the detection results of KRAS mutations in frozen tissue samples by different methods. (DOCX)

Table S3  Summary of the detection results of EGFR mutations in frozen tissue and FFPE tissues detected by different methods. (DOCX)

Acknowledgments
We thank Drs Qiang Liu, Xili Zhao, and Fred Russell Kramer for helpful discussions and technical assistance.

Author Contributions
Conceived and designed the experiments: QL. Performed the experiments: NS XZ. Analyzed the data: NS XZ QL. Contributed reagents/materials/analysis tools: QL. Wrote the paper: NS QL.

References

1. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011–2019.
2. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, et al. (2013) Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31: 759–765.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380–2388.
4. Zhou G, Wu YL, Chen G, Feng J, Liu NX, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735–742.
5. Jacobson DR, Mills NE (1994) A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia. Oncogene 9: 553–563.
6. Neumeister Andrews S, Berivik J, Lovig T, Meling GI, Gaudernack G, et al. (1996) K-RAS mutations and HLA-DR expression in large bowel adenomas. Br J Cancer 74: 99–108.7
7. Dieterle CP, Conzelmann M, Lammennau U, Berger MR (2004) Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-RAS mutations in tissue samples of 199 colorectal cancer patients. Clin Cancer Res 10: 641–650.
8. Chen CY, Shiels SC, Wu SJ (2004) Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis comparison with restriction fragment length polymorphism analysis. Clin Chem 50: 481–489.
9. Loo JD, Chan EC, Shih CL, Chen TL, Liang Y, et al. (2006) Detection of rare mutant Kras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res 34: e12.
10. Oh JE, Lim HS, An CH, Jeong EG, Han JY, et al. (2010) Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes. J Mol Diagn 12: 410–424.
11. Thiele C, Bayerdorffer E, Blaszyk R, Witting B, Neubauer A (1996) Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 24: 903–904.
12. Newton CR, Graham A, Herpinat IE, Powell SJ, Summers C, et al. (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17: 2503–2516.
13. Morlan J, Baker J, Nincicop D (2009) Mutation detection by real-time PCR: a review, robust and highly selective method. Lab Chip 9: 4580–4590.
14. Lee et al. (2013) Highly sensitive EGFR mutation detection by specific amplification of mutant alleles. Exp Mol Pathol 96: 85–91.
15. Nickerson DA, Kaiser R, Lappin S, Stewart J, Hood L, et al. (1990) Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay. Proc Natl Acad Sci U S A 87: 8923–8927.
16. Harden SV, Thomas DC, Benoit N, Minhas K, Westra WH, et al. (2004) Real-time gap ligase chain reaction: a rapid semiquantitative assay for detecting p53 mutation at low levels in surgical margins and lymph nodes from resected lung and head and neck tumors. Clin Cancer Res 10: 2379–2385.
17. Li J, Wang L, Mamoon H, Kalke MH, Berbeco R, et al. (2006) Replacing PCR with GOLD-PCT enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 14: 579–581.
18. Vogelstein B, Kinzler KW (1999) Digital PCR. Proc Natl Acad Sci U S A 96: 9256–9241.
19. Yung TK, Chan KC, Mok TS, Tong J, To KF, et al. (2009) Single-molecule detection of epidermal growth factor receptor mutations in plasma by polynucleotide directed PCR in non-small cell lung cancer patients. Clin Cancer Res 15: 2076–2081.
20. Taly V, Pekin D, Bernheim L, Kotsopoulos SL, Le Corre D, et al. (2013) Multiplex droplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 59: 1722–1731.
21. Altimari A, de Biasi D, De Maglio G, Grappioni E, Capizzi E, et al. (2013) 454 next-generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. Onco Targets Ther 6: 1057–1064.
22. Parsons BL, Marchant-Miros KE, Deongeamp RR, Verkler TL, Patterson TA, et al. (2010) ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. Cancer Invest 28: 364–375.
23. Molinar F, Felicioni L, Bucarino M, De Dosso S, Buttitta F, et al. (2011) Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 17: 4901–4914.
24. Schwarzenbach H, Houen DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426–437.
25. Srinivasan M, Shemak D, Jewell S (2002) Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 161: 1961–1971.
26. Gilbert MT, Haseldorn T, Bunce M, Sanchez JJ, Lucas SB, et al. (2007) The isolation of nucleic acids from fixed, paraffin-embedded tissues—which methods are useful when? PLoS One 2: e537.
27. Moullere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, et al. (2011) High fragmentation characterizes tumour-derived circulating DNA. PLoS One 6: 25418.
28. Liu Q, Sommer SS (2000) Pyrophosphorylation-activated polymerization (PAP): application to allele-specific amplification. Biotechniques 29: 1075–1079, 1081, 1085 passim.
29. Liu Q, Sommer SS (2002) Pyrophosphorolysis-activatable oligonucleotides may facilitate detection of rare alleles, mutation scanning and analysis of chromatin structures. Nucleic Acids Res 30: 598–604.

30. Liu Q, Sommer SS (2004) Detection of extremely rare alleles by bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification (Bi-PAP-A): measurement of mutation load in mammalian tissues. Biotechniques 36: 156–166.

31. Liu Q, Sommer SS (2004) PAP: detection of ultra rare mutations depends on P* oligonucleotides: “sleeping beauties” awakened by the kiss of pyrophosphorolysis. Hum Mutat 23: 426–436.

32. Hou Y, Zhang H, Miranda L, Lin S (2010) Serious overestimation in quantitative PCR by circular (supercoiled) plasmid standard: microalgal pcna as the model gene. PLoS One 5: e9545.

33. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985–990.

34. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611–622.

35. Madke J, Piperno-Neumann S, Servois V, Rampanou A, Mildner M, et al. (2012) Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer Res 18: 3934–3941.

36. Cushman-Vokoun AM, Crowley AM, Rapp SA, Greiner TC (2013) Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer. Am J Clin Pathol 140: 7–19.

37. Ángulo B, García-Garcia E, Martínez R, Suárez-Gauthier A, Conde E, et al. (2010) A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 12: 292–299.